Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 329.00
Bid: 327.50
Ask: 330.00
Change: 0.50 (0.15%)
Spread: 2.50 (0.763%)
Open: 323.00
High: 329.50
Low: 323.00
Prev. Close: 328.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: DFS Furniture gains share of weak market

Thu, 21st Sep 2023 09:40

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

----------

SMALL-CAP - WINNERS

----------

DFS Furniture PLC, up 4.9% 112.45p, 12-month range 101p-170p. The sofa retailer continues to win UK market share in a "very tough market" during its financial year, which ended on June 25, and outlines a path to improving margins. DFS says revenue from continuing operations fell 5.2% year-on-year to GBP1.09 billion from GBP1.15 billion, as pretax profit slumps 49% to GBP29.7 million from GBP58.5 million. Underlying profit before tax and brand amortisation is GBP30.6 million, which is in line with its interim guidance. DFS expects underlying profit before tax and brand amortisation to improve by a low single-digit percentage in financial 2024 to a GBP30 million to GBP35 million range. This assumes market volumes fall 5%, DFS notes. "We are confident the market will recover; however we can't predict how quickly that will happen. We have a clear route to a 5% [profit before tax] margin without market recovery, supported by further margin improvement, new cost efficiencies, and continued growth in Home," DFS says.

----------

Oxford BioMedica PLC, up 5.4% at 283.50 pence, 12-month range 236.50-575.00p. The cell and gene therapy company adds to Wednesday's gains after it announced exclusive talks with Institut Meriueux SA about buying ABL Europe, a pure-play European contract development and manufacturing organization. As part of the deal, Institut Merieux would become one of its major shareholders. The stock is down 16% over the past month however.

----------

SMALL-CAP - LOSERS

----------

James Fisher & Sons PLC, down 2.5% at 345.14p, 12-month range 241p-427.5p. The marine services swings to a pretax loss in the first half of 2023 of GBP4.4 million from a profit of GBP5.2 million a year before. This comes despite revenue rising 17% GBP252.0 million from GBP215.0 million. The loss is due to GBP9.3 million in refinancing legal and advisory costs, as well as higher interest rates, offsetting a positive operating performance, James Fisher explains. "All three divisions delivered revenue and profit growth against the first half of 2022, with a particularly strong increase seen in the Energy division," says CEO Jean Vernet. Trading in July and August is in line with its expectations, and James Fisher leaves its full-year expectations unchanged.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Dec 2020 14:29

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

Read more
9 Nov 2020 10:01

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Read more
9 Nov 2020 09:16

Oxford Biomedica strikes collaboration agreement with PhoreMost

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.

Read more
4 Nov 2020 09:40

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

Read more
30 Oct 2020 08:47

Oxford Biomedica partner delays Parkinson's disease treatment trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.

Read more
23 Oct 2020 15:15

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

Read more
6 Oct 2020 14:19

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Read more
6 Oct 2020 09:44

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Read more
6 Oct 2020 07:55

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

Read more
6 Oct 2020 07:43

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

Read more
6 Oct 2020 07:03

Oxford Biomedica new manufacturing suite approved

(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.

Read more
17 Sep 2020 10:43

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Read more
17 Sep 2020 08:35

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

Read more
17 Sep 2020 07:52

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

Read more
17 Sep 2020 07:01

Oxford Biomedica sees swing to FY profit on Covid vaccine hopes

(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.